View Older Stories View More Recent Stories

Mar 14, 2017 05:00AM Pfizer Launches Zavicefta™ (ceftazidime-avibactam) in the U.K. and Germany, a New Antibiotic to Treat Complicated Infections Caused by Gram-Negative Bacteria
Mar 9, 2017 06:29AM Servier, Pfizer (PFE) Announce FDA Clearance of IND Application for UCART19 for B-ALL (CLLS)
Mar 9, 2017 02:00AM Servier and Pfizer Announce FDA Clearance of IND Application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia
Mar 6, 2017 08:34AM Bristol-Myers Squibb (BMY), Pfizer (PFE) to Present New Analyses of Eliquis and Real-World Data at ACC
Mar 6, 2017 08:30AM Bristol-Myers Squibb and Pfizer to Present New Analyses of Eliquis™ (apixaban) Clinical and Real-World Data at the American College of Cardiology 2017 Scientific Session
Mar 6, 2017 08:02AM Merck (MRK), Pfizer (PFE) Announce FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines
Mar 1, 2017 04:25PM Spark Therapeutics (ONCE), Pfizer (PFE) Announce SPK-9001 Granted Access to PRIME by EMA
Mar 1, 2017 04:15PM Spark Therapeutics and Pfizer Announce that SPK-9001, an Investigational Hemophilia B Medicine, has been Granted Access to the PRIority MEdicines (PRIME) Program by the European Medicines Agency
Feb 28, 2017 06:53PM Pfizer Prices €4,000,000,000 Debt Offering
Feb 28, 2017 07:17AM Pfizer (PFE), EMD Serono Report FDA Accepts BLA for Avelumab for Treatment of Metastatic Urothelial Carcinoma for Priority Review
Feb 28, 2017 07:00AM FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review
Feb 23, 2017 04:15PM Ronald E. Blaylock Elected to Pfizer’s Board of Directors
Feb 21, 2017 08:09AM Pfizer (PFE) BLA for Inotuzumab Ozogamicin Accepted by FDA
Feb 21, 2017 08:00AM Pfizer Announces Acceptance of Regulatory Submission for Inotuzumab Ozogamicin by the U.S. Food and Drug Administration
Feb 17, 2017 12:07PM Pfizer (PFE) Says Data in CD Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA and REMICADE
Feb 17, 2017 12:00PM New Data in Crohn’s Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA® and REMICADE®a
Feb 16, 2017 08:10AM Pfizer (PFE) Announces Top-Line Results from Trial of XELJANZ Compared to Humira
Feb 16, 2017 08:00AM Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ® (tofacitinib citrate) Compared to Humira® (adalimumab)
Feb 14, 2017 03:11PM Eaton Park's 13F Shows New Stakes in Bank of America (BAC), Comcast (CMCSA), Comerica (CMA) (More...)
Feb 9, 2017 08:30AM Relationship Expert Teams Up with Pfizer to Address Intimacy and Relationship Issues for People Living with Chronic Diseases
Feb 3, 2017 08:11AM Pfizer (PFE) Enters Agreement for $5B Accelerated Share Repurchase
Feb 3, 2017 08:10AM Pfizer Commences $5 Billion Accelerated Share Repurchase
Jan 27, 2017 07:01AM Pfizer (PFE) XELJANZ Gains Positive CHMP Opinion to Treat RA
Jan 27, 2017 07:00AM Pfizer Receives Positive CHMP Opinion in Europe for XELJANZ® (tofacitinib citrate) for the Treatment of Moderate to Severe Active Rheumatoid Arthritis
Jan 26, 2017 08:01AM Pfizer (PFE) Announces Positive Top-Line Results from Phase 2 Study of C. difficile Vaccine
Jan 26, 2017 08:00AM Pfizer Announces Positive Top-Line Results from Phase 2 Study of Investigational Clostridium difficile Vaccine for the Prevention of C. difficile Infection
Jan 5, 2017 08:32AM Pfizer (PFE) REFLECTIONS B538-02 Study for PF-06410293 Met Primary Objective
Jan 5, 2017 08:30AM Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for PF-06410293, a Potential Biosimilar to Humira®1 (adalimumab)
Dec 23, 2016 06:21AM Pfizer (PFE) Completes Acquisition of AstraZeneca's (AZN) Small Molecule Anti-Infective Business
Dec 23, 2016 02:05AM Pfizer Completes Acquisition of Small Molecule Anti-Infective Business From AstraZeneca
Dec 21, 2016 08:30AM Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
Dec 21, 2016 08:05AM Pfizer (PFE) Announces sNDA Accepted for IBRANCE in HR+, HER2- Metastatic Breast Cancer
Dec 21, 2016 08:00AM FDA Accepts Supplemental New Drug Application for Pfizer’s IBRANCE® (palbociclib) in HR+, HER2- Metastatic Breast Cancer
Dec 19, 2016 08:04AM Portola Pharma (PTLA) Enters $50M Loan Agreement with Bristol-Myers Squibb (BMY) and Pfizer (PFE) to Continue AndexXa Development
Dec 19, 2016 08:00AM Portola Pharmaceuticals Enters into $50 Million Loan Agreement with Bristol-Myers Squibb and Pfizer for Continued Development of AndexXa™ (andexanet alfa)
Dec 19, 2016 07:01AM Pfizer (PFE) Announces EC Approval for Nimenrix in Infants Six Weeks of Age and Older
Dec 19, 2016 07:00AM Pfizer Receives Approval in the European Union for Nimenrix™ (Meningococcal Group A, C, W-135, and Y Conjugate Vaccine) in Infants Six Weeks of Age and Older
Dec 16, 2016 02:10PM Pfizer (PFE) Announces FDA Approves Removal of Boxed Warning From CHANTIX Labeling
Dec 16, 2016 02:09PM FDA Approves Removal Of Boxed Warning Regarding Serious Neuropsychiatric Events From CHANTIX® (varenicline) Labeling
Dec 15, 2016 06:04AM Pfizer (PFE) Confirms FDA Approval for EUCRISATM for Eczema
Dec 14, 2016 07:34PM Pfizer Receives FDA Approval for EUCRISATM (crisaborole), a Novel Non-Steroidal Topical Ointment for Mild to Moderate Atopic Dermatitis (Eczema)
Dec 14, 2016 04:30PM Sheridan Memorial Hospital First to Implement Interoperable Alarm Technology Between Cerner and Hospira
Dec 12, 2016 11:53AM Pfizer Declares First-Quarter 2017 Dividend
Dec 5, 2016 08:00AM Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia
Dec 5, 2016 06:49AM Spark Therapeutics (ONCE), Pfizer (PFE) Announce Prelim. Data from SPK-9001 Phase 1/2 in Hemophilia B
Dec 5, 2016 06:26AM Pfizer (PFE) Announces Data from Glasdegib Phase 2 in AML; Favorable OS Results Noted
Dec 3, 2016 01:00PM New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Dec 3, 2016 11:00AM Spark Therapeutics and Pfizer Present Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting
Dec 1, 2016 12:51PM IBM (IBM) Watson Health and Pfizer (PFE) Enter Drug Discovery Collaboration
Dec 1, 2016 08:06AM Pfizer (PFE) Announces LYRICA Phase 3 in Pediatric Epilepsy Met Primary Endpoint
View More Recent Stories View Older Stories